Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05104047 · ClinicalTrials.gov registry record · NA

Distal Peripheral Neuropathy in Type 2 Diabetes

A NA study of Diabetes and Peripheral Neuropathy, sponsored by New York University.

Completed
Registry status
NA
Development phase
44
Enrollment target
2
Study locations

NCT05104047: Completed NA study of Diabetes and Peripheral Neuropathy, sponsored by New York University.

NCT05104047 is a NA study of Diabetes and Peripheral Neuropathy that has completed, run by New York University. The registered enrollment target is 44 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05104047, a NA study of Diabetes and Peripheral Neuropathy, has completed, sponsored by New York University.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target
2
Study locations

Study Summary

Distal sensory peripheral neuropathy (DSP) is a chronic, debilitating painful condition affecting quality of life in persons living with Type 2 diabetes. Treatments prescribed to manage DSP pain, such as nonnarcotic and narcotic analgesics, antidepressants and anticonvulsants, are largely ineffective. This is a preliminary study at assessing the feasibility, efficiency and preliminary efficacy of a novel non-pharmacologic pain management approach, moxibustion, to reduce DSP pain and improve quality of life.

Primary Outcome

The GPS is a Likert magnitude-estimation log-scale of sensory pain. Subjects rate their DSP pain by selecting one of 13 words to describe their average and worst DSP pain. "Nothing"=0 to "Extremely intense"=12

Interventions

  • OTHER Moxibustion - Traditional (Active)
  • OTHER Moxibustion - Smokeless - (Active)
  • OTHER Placebo Moxibustion

Study Locations (2)

New York

  • New York University, Division of Special Studies in Symptom Management - New York
  • NYU Special Studies in Symptom Management - New York

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2019-07-29
Est. Completion 2022-08-30
Phase NA
New York University

83 total trials

What the finished NCT05104047 record still lists

NCT05104047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Moxibustion - Traditional (Active) is the first listed.

NCT05104047 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05104047 about?

NCT05104047 is a clinical study titled "Distal Peripheral Neuropathy in Type 2 Diabetes". Distal sensory peripheral neuropathy (DSP) is a chronic, debilitating painful condition affecting quality of life in persons living with Type 2 diabetes. Treatments prescribed to manage DSP pain, such as nonnarcotic and narcotic analgesics, antidepressants and anticonvulsants, are largely ineffectiv...

What is the current status of trial NCT05104047?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2019-07-29. Estimated completion is 2022-08-30.

What conditions does trial NCT05104047 study?

This clinical trial studies the following conditions: Diabetes, Peripheral Neuropathy, Pain, Neuropathic.

What interventions are being tested in trial NCT05104047?

The interventions under investigation include: Moxibustion - Traditional (Active) (OTHER), Moxibustion - Smokeless - (Active) (OTHER), Placebo Moxibustion (OTHER).

Who is sponsoring clinical trial NCT05104047?

This trial is sponsored by New York University, which has 83 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05104047 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05104047's enrollment target sits among peer trials

44 257th of 338 higher than 80 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05104047, the US trial registry maintained by the National Library of Medicine. NCT05104047 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.